{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:50:51Z","timestamp":1791802251944,"version":"4.3.4"},"reference-count":22,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JPGN rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pediatric obesity and metabolic dysfunction\u2010associated steatotic liver disease (MASLD) prevalence has risen markedly over the past decade. Due to transition delays and workforce shortages, pediatric specialists often manage patients into young adulthood, and thus familiarity with adult pharmacotherapies for MASLD is essential. Currently, Semaglutide, a glucagon\u2010like peptide\u20101 (GLP\u20101) receptor agonist, is approved for adults with metabolic dysfunction\u2010associated steatohepatitis (MASH) and F2\u2013F3 fibrosis; however, dual and triple agonists are being evaluated. Tirzepatide, a dual agonist that targets gastric inhibitory peptide (GIP) and the GLP\u20101 receptor, has demonstrated superior weight reduction to Semaglutide (\u221220.2% vs. \u221213.7%) with a more favorable gastrointestinal adverse effect profile. Adult literature has demonstrated its effectiveness in MASH resolution, and pediatric data suggest it is safe in younger populations. Currently, there are no pediatric\/adolescent studies exploring the use of Tirzepatide in MASLD. We present our experience using Tirzepatide in two adolescent patients with obesity and MASLD.<\/jats:p>","DOI":"10.1002\/jpr3.70246","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:41:11Z","timestamp":1791801671000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tirzepatide use in adolescents with metabolic dysfunction\u2010associated steatotic liver disease (MASLD): A case series"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-6824","authenticated-orcid":false,"given":"Brandon J.","family":"Perumpail","sequence":"first","affiliation":[{"name":"Department of Pediatric Gastroenterology, Hepatology, and Nutrition Children's Hospital of Philadelphia  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2001-6825","authenticated-orcid":false,"given":"Andrea","family":"Tou","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Hepatology, and Nutrition Children's Hospital of Philadelphia  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Panganiban","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Hepatology, and Nutrition Children's Hospital of Philadelphia  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-1212"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2012.08.043"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12219"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001368"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100164"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.02.006"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_10_10_1","unstructured":"ZEPBOUND (Tirzepatide). Prescribing Information. Published January 2026. Accessed February 19 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/217806s002lbl.pdf"},{"key":"e_1_2_10_11_1","unstructured":"MOUNJARO (Tirzepatide). Prescribing Information. Published January 2026. Accessed February 19 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215866s009lbl.pdf"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01774-X"},{"key":"e_1_2_10_15_1","unstructured":"Wegovy (Semaglutide). Prescribing Information. Published August 2025. Accessed January 9 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s024lbl.pdf"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001216"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002535"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.12.009"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000197"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1093"},{"key":"e_1_2_10_21_1","unstructured":"Rezdiffra (Resmetirom). Prescribing Information. Published March 2024. Accessed January 9 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217785s000lbl.pdf"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16151"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70143"}],"container-title":["JPGN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpr3.70246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jpr3.70246","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpr3.70246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:41:14Z","timestamp":1791801674000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpr3.70246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":22,"alternative-id":["10.1002\/jpr3.70246"],"URL":"https:\/\/doi.org\/10.1002\/jpr3.70246","archive":["Portico"],"relation":{},"ISSN":["2691-171X","2691-171X"],"issn-type":[{"value":"2691-171X","type":"print"},{"value":"2691-171X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"2026-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jpr3.70246"}}